RxDoctor Payments Data

Soroush Aghigh, MD

Internal Medicine · Key Biscayne, FLNPI 1790836997

Payments from drug & device makers

$428,938in general payments, 2019–2025

Across 31 payments — averaging $13,837 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$307K
  • Teva Pharmaceuticals USA, Inc.$99K
  • Genentech, Inc.$22K
  • Abbott$149
  • Mylan Specialty L.p.$23
$1,366in research payments, 2019–2025

Across 1 payment — averaging $1366.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

What the payments were for

  • Food & beverage$172100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly1$307,447
Teva Pharmaceuticals USA, Inc.23$98,897
Genentech, Inc.5$22,421
Abbott1$149
Mylan Specialty L.p.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$428,938 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$362,574
Medicare patients
463
Services billed
3,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$32,249
EntrestoSacubitril/Valsartan18$16,007
BrilintaTicagrelor28$14,278
Quetiapine Fumarate ErQuetiapine Fumarate13$778
ClopidogrelClopidogrel Bisulfate59$717
Pantoprazole Sodium39$350
Atorvastatin Calcium47$278
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$194
Metoprolol Tartrate19$143
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$137
Metoprolol Succinate20$127
Methocarbamol15$124
Amiodarone Hcl14$123
Furosemide24$99
Lisinopril13$72

Paid to pharmacies, not to this prescriber.

Other internal medicine in Key Biscayne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →